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Abstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, 
with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial 
prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary 
tract infection and acute urinary retention. Medical treatments of symptomatic BPH include; 
1) the 5α-reductase inhibitors, 2) the α1-adrenergic antagonists, and 3) the combination of a 
5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists relax 
the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of 
the bladder wall, thus decreasing the resistance to urine flow without compromising bladder 
contractility. Clinical trials have shown that α1-adrenergic antagonists decrease LUTS and 
increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk 
of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase decrease produc-
tion of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased 
peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention 
and need for surgical intervention. Interim results of the ongoing Combination of Avodart and 
Tamsulosin (CombAt) study have shown combination therapy with the 5α-reductase inhibitor 
dutasteride and the α1-adrenergic antagonist tamsulosin offer significant improvements from 
baseline compared with either drug alone.
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Introduction
Benign prostatic hyperplasia (BPH) refers to stromal and glandular epithelial hyperplasia 
that occurs in the zone of the prostate that surrounds the urethra. In the absence of 
histopathology, the clinical term benign prostatic enlargement (BPE) is used to describe 
the presumed etiology of associated lower urinary tract symptoms (LUTS), including 
urinary frequency and urgency, a sensation of incomplete bladder emptying, a weak and 
interrupted urinary stream, straining to initiate urination, and nocturia. The prevalence of 
LUTS due to BPH/BPE increases with increasing age, and moderate to severe symptoms 
occur in up to 40% of men after age 60. Symptoms are evaluated with validated instru-
ments such as the American Urologic Association (AUA) Symptom Index and the 
International Prostate Symptom Score (IPSS). Each of seven symptoms (frequency, 
urgency, weak stream, intermittency, incomplete emptying, straining to urinate, and 
nocturia) are scored by the patient on a 0–5 scale based on their frequency. A score of 
less than 7 indicates mild symptoms; a score of 8–19 indicates moderate symptoms, and a 
score of greater than 19 indicates severe symptoms. In addition to symptoms that may have 
a negative impact on the quality of life, BPH/BPE can result in acute urinary retention, Clinical Interventions in Aging 2009:4 252
Miller and Tarter Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
recurrent urinary tract infections (UTI), bladder stones, urinary 
incontinence, gross hematuria and renal failure.
The natural history of BPH/BPE is unpredictable in 
individual men. In a study of men who were followed 
expectantly for 5 years without treatment, 31% reported 
symptomatic improvement whereas 16% reported symptomatic 
worsening.1 Men with symptomatic BPH/BPE have a 23% 
lifetime risk of developing acute urinary retention if left 
untreated.2 A man over age 60 years with obstructive symp-
toms has a 39% probability of undergoing surgery related to 
the prostate within 20 years.3
The American Urological Association and the European 
Association of Urology have published recommendations 
for the evaluation of men with LUTS, and the treatment 
of men with symptomatic BPH/BPE. Medical therapies 
recommended by these two organizations include the 
α1-adrenergic antagonists terazosin, doxazosin, tamsulosin, 
and alfuzosin, and the 5α-reductase inhibitors finasteride 
and dutasteride.4
Selective α1-adrenergic antagonists relax the smooth 
muscle of the prostate and bladder neck without affecting 
the detrusor muscle of the bladder wall, thus decreasing 
the resistance to urine flow without compromising bladder 
contractility. Randomized, placebo-controlled clinical trials 
have shown that α1-adrenergic antagonists decrease LUTS 
and increase urinary flow rates in men with symptomatic 
BPH/BPE. However, a positive placebo effect was also 
demonstrated for both symptom score and peak urinary flow 
rates in these trials. Common side effects include dizziness, 
headache, asthenia and postural hypotension, which occur in 
5% to 9% of patients.5 Tamsulosin is the most uroselective 
α1-adrenergic antagonist approved for use in the treatment of 
symptomatic BPH/BPE. Clinical trials have shown postural 
hypotension was observed less frequently with tamsulosin 
than with either terazosin or doxazosin.6
Dihydrotestosterone (DHT) is the product of the 
conversion of testosterone by the enzyme 5α-reductase, and 
is produced in the tissues of the liver, skin and organs that 
originate from the mesonephric duct, such as the prostate. 
Within the prostate, locally produced DHT acts in a paracrine 
fashion to stimulate growth. Inhibitors of 5α-reductase 
decrease production of DHT within the prostate resulting 
in decreased prostate volume, increased peak urinary flow 
rates, and improvement in symptom scores. Studies have also 
shown that 5α-reductase inhibitors reduce serum levels of 
prostate specific antigen and reduce the overall risk of prostate 
cancer.7 Side effects of 5α-reductase inhibitors include 
erectile dysfunction, decreased libido, ejaculatory dysfunction 
and gynecomastia, which occur in less than 5% of patients.8 
Dutasteride inhibits both type 1 and type 2 5α-reductase 
isoenzymes, whereas finasteride inhibits only type 2.
Combination therapy with the α1-adrenergic antagonist 
doxazosin and the 5α-reductase inhibitor finasteride has 
been shown in previous trials to significantly reduce the 
overall risk of clinical progression of BPH/BPE compared 
to the use of either drug alone. Herein we detail the use of 
the 5α-reductase inhibitor dutasteride and the α1-adrenergic 
antagonist tamsulosin, and review the role of combination 
therapy in the medical treatment of LUTS caused by prostatic 
enlargement.
Pharmacology, mode of action, 
and pharmacokinetics of dutasteride
Dutasteride is in a drug class known as 17β-substituted 
4-aza-steroids with the chemical name (5α, 17β)-N {2, 5, 
bis(trifluoromethyl) phenyl}-3-oxo-4-azaandrost-1-ene-
17-carboxamide. The structural formula is shown in Figure 1. 
It is a competitive inhibitor of type 1 and type 2 5α-reductase 
isoenzymes. It forms a stable complex with a slow rate of 
dissociation, and does not bind the androgen receptor. The 
bioavailability of dutasteride is approximately 60% and 
peak serum concentration is achieved after 2 to 3 hours. 
The time to steady state is dose dependent, and at a dose of 
0.5 mg/day is approximately 3 months. More than 99.5% 
of circulating dutasteride is bound to plasma proteins, and 
has a volume of distribution of 300 to 500 L. Clearance is 
linear at 0.58 L/hour, resulting in a half-life of up to 5 weeks. 
Pharmacokinetic data are summarized in Table 1. Dutaste-
ride is detectable (greater than 0.1 ng/mL) in the serum 4 to 
6 months after discontinuation of treatment. The drug is 
extensively metabolized by cytochrome-P3A4 in the liver 
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are excreted in the urine. Following dosing to steady state, 
5 major metabolites are detectable in the serum. The major 
metabolite, 6β-hydroxydutasteride, has pharmacological 
activity comparable to dutasteride.9
Caution should be used when administering the drug in 
patients with hepatic impairment, and in patients who take 
drugs that inhibit cytochrome-P3A4 (verapamil, diltiazem, 
and ritonavir) because the pharmacokinetics and risk of side 
effects may be altered. No other significant drug interactions 
have been identified.
In three pooled 2-year studies, the most frequent side 
effects were impotence, decreased libido, gynecomastia, and 
ejaculatory dysfunction. The incidence of side effects compared 
to placebo was increased from 4% to 7.3% for impotence, 2.1% 
to 4.2% for decreased libido, 0.7% to 2.3% for gynecomastia, 
and 0.8% to 2.2% for ejaculatory dysfunction.10
No dose adjustment is necessary in the elderly. Of 2617 
men treated with dutasteride in three pivotal studies, 60% 
were age 65 and over and 15% were age 75 and over. In 
these studies no overall difference in safety or efficacy was 
observed between older and younger patients. No change 
in bone mineral density as measured on dual energy x-ray 
absorptiometry was observed compared with placebo. Plasma 
lipid profiles were unaffected.11
Dutasteride is not indicated for use in women and the 
pharmokinetics have not been investigated in patients 
younger than 18 years. Due to potential adverse effects on 
normal development of the male reproductive tract, use of 
dutasteride should be avoided in men less than 18 years of 
age, and is absolutely contraindicated in women of repro-
ductive age.11
Efficacy and safety of dutasteride
The efficacy and safety of dutasteride was studied in 
three parallel, randomized, placebo-controlled trials over 
a period of 2 years. A total of 4325 men age 50 years or 
older with moderate to severe symptomatic BPH/BPE (AUA 
symptom score of 12 or more and peak urinary flow rate of 
15 mL/sec or less) and prostate volume greater than 30 cm3 
were randomized to receive either dutasteride 0.5 mg/day 
or placebo. Endpoints included changes in prostate volume, 
peak urinary flow rate, risk of surgical intervention, safety 
and tolerability, and measurements of serum PSA, testos-
terone, and DHT.10
The mean improvement in symptom score in the placebo 
groups was 2.3 (±6.8) to 14.7 (±7.2) from a baseline of 17.1 
(±6.1, p  0.001). In the dutasteride groups, a 4.5-point 
(±6.6) improvement to a mean of 12.2 (±6.6) was significant 
compared to baseline of 17.0 (±6.0, p  0.001) and compared 
with placebo groups (p  0.001). Peak urinary flow rates 
in the placebo groups increased by 0.6 mL/sec (±4.7) to 
11.2 mL/sec (±4.8), which was significant compared with 
baseline of 10.4 mL/sec (±3.6, p  0.001). Peak urinary 
flow rates in the dutasteride groups increased by a mean 
of 2.2 mL/sec (±5.2) to 12.5 (±5.6), which was significant 
compared to baseline of 10.1 mL/sec (±3.5, p  0.001), 
and to the placebo groups (p  0.001). After 24 months 
of therapy, the mean total prostate volume increased by 
12.4% in the placebo groups and decreased by 20.4% in the 
dutasteride groups (p  0.001). The relative risk of acute 
urinary retention in the dutasteride groups compared with 
the placebo groups was 0.43, or a risk reduction of 57% 
(p  0.001). The relative risk of surgical intervention in the 
dutasteride groups compared to the placebo groups was 0.52, 
or a risk reduction of 48% (p  0.001). Significant changes 
in serum DHT (16 (±150) vs –389 (±228) pg/mL) and PSA 
(0.5 (±2.1) vs –2.2 (±2.0) ng/mL), as well as a significantly 
larger increase in serum testosterone (36 (±1226) vs 749 
(±1475) pg/mL) were noted in the dutasteride groups 
compared to the placebo groups (p  0.001 for each 
comparison).10
Adverse events attributed to the study drug were reported 
in 14% of men in the placebo groups and in 19% of men 
in the dutasteride groups. A higher proportion of men in 
the dutasteride groups than in the placebo groups reported 
impotence, reduced libido, ejaculatory dysfunction, and 
gynecomastia.10 Results are summarized in Table 2.
Data from several open-label extensions of the above 
three parallel, randomized placebo-controlled trials have 
Table 1 Pharmacokinetics of dutasteride
Bioavailability 60%
Steady state 3 months
Peak serum concentration 2–3 hours
volume of distribution 511 L
Elimination half-life 5 weeks
Table 2 Sexual adverse events from dutasteride efficacy and safety 
study
Adverse event Placebo Dutasteride
Impotence 4.00% 7.30%
Decreased libido 2.10% 4.20%
Gynecomastia 0.70% 2.30%
ejaculation disorder 0.80% 2.20%Clinical Interventions in Aging 2009:4 254
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recently been reported. These studies show continued 
tolerability and efficacy after 48 months of treatment. In these 
trials less than 1% of the men withdrew from the open-label 
extension because of sexual dysfunction. Approximately 1% 
of men withdrew because of gynecomastia. Patients who 
received dutasteride during both study phases showed greater 
improvement in symptom scores and urinary peak flow rates 
than those initially receiving placebo.5,12,13
Effect of dutasteride  
on quality of life
Data regarding the impact on quality of life of the 4325 men 
in the three randomized, double-blind, placebo controlled, 
2-year studies detailed above have also been reported. At 
2 years, dutasteride, but not placebo, resulted in clinically 
and statistically significant improvements from baseline in 
the BPH Impact Index (BII) score after 6 months of treat-
ment. This net improvement from baseline increased from 
6 months to 2 years.14
Additional data were recently reported from a separate 
prospective, multi-center, open-label study evaluating the 
improvement in symptoms and quality of life in patients with 
symptomatic BPH/BPE treated with dutasteride. Patients 
received dutasteride 0.5 mg/day for 24 weeks. The primary 
endpoint was the proportion of patients who achieved at least 
a 3-point decrease from baseline in IPSS. The secondary 
endpoints were changes in quality of life (IPSS item 8) and 
patient discomfort and satisfaction, assessed using the visual 
analogue scale (VAS).
A total of 366 patients from 72 centers were included in 
the study. After 24 weeks of treatment with dutasteride, 72.5% 
of patients achieved at least a 3-point reduction in IPSS. 
The mean IPSS score decreased from 15.3 (±6.4)at baseline 
to 9.1 (±5.6, p  0.001) at 24 weeks. Patients with more 
severe symptoms had a higher probability of improvement 
in the IPSS. There were statistically significant decreases in 
all individual IPSS items, with greater improvement seen in 
items related to irritative and obstructive voiding symptoms 
than in those items related to storage symptoms.
Patient quality of life improved as assessed by IPSS 
item 8 with a mean improvement of 38.7% from baseline 
(p  0.001). Patient discomfort and satisfaction also 
significantly improved. The mean VAS for discomfort 
decreased from 48.9 at baseline to 28.6 (p  0.001) at 
24 weeks. Patient VAS scores for satisfaction increased from 
a baseline at both 12 and 24 weeks (p  0.001).
Overall, 77 (19%) patients had at least one adverse event 
related to dutasteride during the study period, including 
erectile dysfunction (7%), decreased libido (4%), and 
gynecomastia (2%).15
Dutasteride in prostate cancer 
prevention and treatment
An in depth discussion of the role of 5α-reductase inhibitors 
in the prevention and treatment of prostate cancer is beyond 
the scope of this review; however the clinical implications 
of long-term use of finasteride or dutasteride in the treatment 
of BPH must be considered in light of new information from 
recent trials.
In the Prostate Cancer Prevention Trial (PCPT) 18882 men 
age 55 years or older with a PSA of 3.0 ng/mL or less were ran-
domized to receive finasteride 5 mg or placebo daily for 7 years. 
Prostate biopsies were performed at the end of the 7-year study 
period, or if the annual PSA level (adjusted for the effect of fin-
asteride) was greater than 4 ng/mL, or if the digital rectal exam 
(DRE) was suspicious for prostate cancer. The primary endpoint 
measure was the diagnosis of prostate cancer. The study was 
terminated 15 months early on the recommendations of the data 
and safety monitoring committee because the study objective 
had been met. Prostate cancer was detected in 18.4% of men in 
the finasteride group and in 24.4% of men in the placebo group, 
a relative risk reduction of 24.8% (p  0.001). However, of the 
men who developed prostate cancer, high-grade prostate cancer 
was reported in a higher proportion of men in the finasteride 
group than in the placebo group (37% vs 22%, p  0.001).7 
Androgen deprivation therapy, including inhibition of DHT 
by finasteride, results in specific histopathologic changes in 
prostatic adenocarinoma, which can result in a “grading bias.” 
In the PCPT, most of the high-grade cancer were reported in 
the earlier phase of the study, a finding that is at odds with the 
development of more aggressive cancers with prolonged finas-
teride treatment.16 At the present time FDA-labeled indications 
in the United States for finasteride and dutasteride do not include 
prostate cancer prevention.
An ongoing study, the Reduction by Dutasteride of 
Prostate Cancer Events (REDUCE) Trial will use dutasteride 
in a group of men identified at increased risk of develop-
ing prostate cancer to determine if this dual 5α-reductase 
inhibitor will be an effective chemoprevention agent. Eligible 
men must be between ages 50 and 75 and have a PSA between 
2.5 ng/mL and 10 ng/ml (age 50–60 years) or between 
3.0 ng/mL and 10 ng/mL (age  60 years), and a free PSA 
of 25% or lower at baseline, and a negative prostate biopsy. 
The men are randomized to placebo or dutasteride 0.5 mg 
daily. Prostate biopsies will be performed at 2 years and at 
4 years to evaluate for prostate cancer. Additionally, free and Clinical Interventions in Aging 2009:4 255
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total PSA will be measured every 6 months, with adjustment 
of the PSA of patients randomized to the dutasteride arm. 
The primary endpoint is biopsy-proven prostate cancer after 
2 and 4 years of treatment and the study also aims to address 
the issue of high-grade tumors prospectively. The results of 
the REDUCE trial will have to be employed with the caution, 
as all men included in the already had a negative prostate 
biopsy, which is not the case in clinical practice.
As discussed above, dutasteride inhibits both type 1 
and type 2 5α-reductase isoenzymes whereas finasteride 
inhibits only type 2. Type 2 5α-reductase is the predominate 
isoenzyme in normal and hyperplastic prostate tissue. Recent 
studies have shown that immunohistochemical staining of 
type 1 is enhanced in prostate cancer tissues compared to BPH 
epithelium. This suggests that a dual inhibitor of 5α-reductase 
isoenzymes, such as dutasteride, may be a reasonable agent 
to evaluate for prevention of prostate cancer.17
As information from ongoing trials is compiled, physicians 
who recommend 5α-reductase inhibitors for the treatment of 
patients with symptomatic BPH/BPE should discuss the effect 
of therapy on 1) reduction in the risk of developing prostate 
cancer, and 2) the histopathology of prostate biopsies and 
the potential risk of developing high-grade prostate cancer. 
Prescribing physicians must also ensure that proper drug-effect 
corrections are made to serum PSA values and that vigilance is 
maintained in the form of prostate biopsy, when indicated.
In addition to its potential role in the prevention of 
prostate cancer, dutasteride has been evaluated as a com-
ponent of neoadjuvant androgen deprivation therapy before 
brachytherapy for prostate cancer to reduce prostate volume 
and facilitate seed implantation. In a recently reported study, 
31 patients opted for cytoreductive therapy with bicalutamide 
50 mg and dutasteride 0.5 mg daily. All patients underwent 
transrectal ultrasound volumetric study of the prostate gland, 
with ellipsoid volume determination of the prostate gland and 
transition zone, before initiation of the neoadjuvant therapy 
and at 3 months after initiation. After the 3-month course of 
combination therapy, the average prostate volume decreased 
by 33.6% using the volumetric determination, and decreased 
by 34.6% using the ellipsoid volume determination. The 
average transition zone volume decreased from 20.8 cm3 to 
12.4 cm3, a reduction of 39.8%.18 Although these data are 
not the product of a randomized, placebo-controlled trial, 
the results are consistent with previous studies of androgen 
deprivation therapy, and dutasteride may be a reasonable 
alternative to the use of luteinizing hormone-releasing 
hormone (LHRH) agonists, which have been associated with 
more significant side effects.
Pharmacology, mode of action, 
and pharmacokinetics of tamsulosin
Tamsulosin hydrochloride is a competitive antagonist of 
α1A adrenoreceptors with the chemical name (-)-(R)-5-
[2-[[2-(ο-Ethoxyphenoxy) ethyl]amino]propyl]-2-methoxy-
benzenesulfonamide, monohydrochloride. The structural 
formula is shown in Figure 2. There are three identified α1 
adrenoreceptor subtypes found in human organs and tissue: 
α1A, α1B, and α1D. Approximately 70% of the α1 adrenore-
ceptors in the human prostate are of the α1A subtype. Under 
fasting conditions absorption of the orally administered 
recommended dosage of tamsulosin is greater than 90%. The 
time to maximum concentration is 4 to 5 hours under fasting 
condition and 6 to 7 hours when tamsulosin is administered 
with food. Administration of tamsulosin under fasting condi-
tions results in a 40% to 70% increase in peak concentrations 
compared to the same dosage administered with food. The 
time to steady state is approximately 5 days. More than 94% 
of tamsulosin is bound to circulating plasma proteins and 
the drug has a volume of distribution of 16 L. Tamsulosin 
undergoes restrictive clearance with a systemic clearance of 
2.88 L/hour and a half-life of 9 to 15 hours. Pharmacokinetic 
data are summarized in Table 3.
Tamsulosin is extensively metabolized by cytochrome-
P3A4 and -P2D6 enzymes in the liver and is primarily (76%) 
excreted in the urine with a smaller fraction (21%) excreted 
in the feces. The metabolites of tamsulosin are extensively 
conjugated to glucuronide or sulfate prior to renal excre-
tion. The pharmacokinetics of metabolites have not been 
established.
Dosage adjustment of tamsulosin is not necessary in 
patients with mild-to-severe renal impairment (CLcr  10 
mL/min/1.73 m2) or mild-to-moderate hepatic dysfunction 
(Child-Pugh’s classification A and B). Tamsulosin has not 
been studied in patients with end-stage renal disease or severe 
hepatic dysfunction. Clearance of tamsulosin decreases with 
age-dependent decreases in plasma binding resulting in a 40% 
increased exposure in patients aged 55 to 75 years compared 
with those aged 20 to 32 years. Tamsulosin should be admin-
istered with caution in combination with cimetidine due to 
H2NO2S
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significant (26%) decrease in the clearance of tamsulosin. 
Dosage adjustments are not required for concomminant 
administration of tamsulosin and nifedipine, atenolol, 
enalapril, digoxin, theophylline, or furosemide. Studies of 
interactions in patients receiving warfarin are inconclusive; 
therefore tamsulosin should be administered with caution in 
these patients. Additionally, interactions with moderate to 
strong inhibitors of CYP3A4 and CYP2D6 such as fluoxetine 
and ketoconazole, respectively, have not been studied and 
caution should be exercised.
In six short-term placebo-controlled clinical trials the 
most commonly reported adverse reactions to tamsulosin 
were headache, dizziness, rhinitis and abnormal ejaculation. 
In two of the studies symptomatic postural hypotension 
occurred in 0.2% and 0.4% of patients receiving 0.4  mg 
and 0.8  mg of tamsulosin daily compared with no patients 
in the placebo group.
Intraoperative floppy iris syndrome (IFIS) has been 
observed in some patients undergoing cataract surgery 
while being treated with α1-blockers, including tamsulosin. 
Most cases of IFIS occurred in patients currently taking 
α1-blockers or who had recently discontinued the use 
α1-blockers, but has been reported in patients who discontin-
ued use of α1-blockers as long as 9 months prior to cataract 
surgery. Treating ophthalmologists should be prepared for 
possible modifications to surgical techniques in patients 
treated with α1-blockers, including tamsulosin. The benefit 
of discontinuation of α1-blockers prior to cataract surgery 
has not been established.
Efficacy and safety of tamsulosin
The efficacy and safety of tamsulosin was studied in a 
double-blind, placebo-controlled, randomized, multicenter 
US trial of 0.4 mg and 0.8 mg of tamsulosin daily. A total of 
756 men aged 45 years or older with signs and symptoms of 
BPH/BPE (AUA symptom score 13 or peak urinary flow 
rate 4–15 mL/s) were randomized to tamsulosin 0.4 mg daily, 
tamsulosin 0.8 mg daily, or placebo for a total of 13 weeks. 
Primary end point measures were changes in AUA symptom 
score, percentage of patients with at least 25% improvement 
in AUA symptom score, change in peak urinary flow rate, 
and percentage of patients with at least 30% improvement 
in peak urinary flow rate. Safety was assessed via adverse 
event profiles, orthostatic vital sign measurements, laboratory 
testing, EKG findings and physical examination.6
The mean improvement in the AUA symptom score in 
the placebo group was -5.5 (±6.3) from a mean baseline of 
19.6 (±4.9) compared with –8.3 (±6.3, p  0.001) in the 
0.4 mg/day tamsulosin group and –9.6 (±6.2, p  0.001) in 
the 0.8 mg/day tamsulosin group (p = 0.020 vs 0.4 mg/day). 
Peak urinary flow rates increased a mean of 0.53 mL/s (±3.3) 
in the placebo group and 1.75 mL/s (±3.5) and 1.78 mL/s 
(±3.3) in the 0.4 mg/day and 0.8 mg/day groups, respectively 
(p  0.001). Among patients in the 0.8 mg/day group 74% 
achieved a 25% improvement in AUA symptom score 
compared with 70% in the 0.4 mg/day group and 51% in the 
placebo group (p  0.001 vs 0.4 mg/day and 0.8 mg/day). 
More than 30% of patients in both tamsulosin groups 
had 30% improvement in peak urinary flow rates compared 
to 21% of patients in the placebo group.6
There were no clinically significant differences in 
hematologic tests, EKG results or coagulation parameters in 
patients receiving tamsulosin compared to patients receiving 
placebo. Three patients (one in the placebo group, two in the 
tamsulosin groups) were withdrawn from the study due to 
elevation of liver function test values. No clinically signifi-
cant differences in orthostatic changes to systolic or diastolic 
blood pressure or pulse were found between treatment and 
placebo groups.6
The long-term efficacy and safety of tamsulosin were 
reported in a four year extension, multicenter, open-label, 
phase IIIB clinical study which included patients treated up 
to 6 years with tamsulosin. A total of 609 men aged 45 to 
75 years were included, with 109 patients completing 6 years 
of treatment and 419 completing 5 years of treatment. There 
was continued and sustained improvement in baseline param-
eters including statistically significant yearly improvements 
in AUA symptom score and significant increases in peak 
urinary flow rates. Compared to shorter-term studies the 
incidence of most adverse events was not increased.19
Combination therapy 
with dutasteride and tamsulosin
In 2003 data from the Medical Therapy of Prostate Symptoms 
(MTOPS) Trial, a study of 3047 men with moderate to 
severe symptomatic BPH/BPE, showed the risk of clinical 
progression of BPH/BPE was reduced by 39% in patients 
treated with doxazosin alone, by 34% in patients treated 
with finasteride alone, and by 66% in patients treated with 
Table 3 Pharmacokinetics of tamsulosin
Bioavailability 90%
Steady state 5 days
Peak serum concentration 4–6 hours
volume of distribution 16 L
Elimination half-life 15 hoursClinical Interventions in Aging 2009:4 257
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combination therapy. Similarly, improvements in AUA 
symptom scores were significantly greater in the combina-
tion therapy group than either the doxazosin group or the 
finasteride group. Peak urinary flow rates were improved and 
the risk of surgical intervention was reduced in all treatment 
groups compared with placebo.20
More recently, Roehrborn et al published the preplanned 
two-year results of the Combination of Avodart and Tamsulo-
sin (CombAt) study. Like the MTOPS trial, the CombAT study 
compares the effect of dutasteride alone and tamsulosin alone to 
the outcomes of combination therapy, but with some important 
differences. The CombAT study includes only men at increased 
risk for progression of BPH due to a prostate volume 30 mL 
or a PSA  1.5 ng/mL; these patients represent a subset popula-
tion identified by the MTOPS Trial. Additionally, the MTOPS 
trial used the type-2 5α-reductase inhibitor finasteride whereas 
the CombAT study assesses the results of treatment using the 
dual 5α-reductase inhibitor dutasteride.21
The CombAT study is an ongoing 4-year randomized, 
double-blind parallel group study involving 446 investigators 
in 35 countries. The aim of the study is to investigate the long-
term clinical outcomes of patients with BPH/BPE treated 
with dutasteride alone, tamsulosin alone, and combination 
therapy. A total of 4838 subjects have been enrolled. The 
primary endpoint at the end of the initial 2-year study period 
was the change in IPSS from baseline. Secondary endpoints 
included IPSS responders (25%, 2-point, and 3-point 
improvement), peak urinary flow rate, peak urinary flow rate 
responders (30% and 3 mL/s improvement), total pros-
tate volume, and prostate transition zone volume. At 2 years 
the mean decrease from IPSS baseline was 4.3 (±0.15) for 
the tamsulosin group, 4.9 (±0.15) for the dutasteride group, 
and 6.2 (±0.15) for the combination group (p  0.001). 
A statistically significant difference was achieved for com-
bination therapy over dutasteride alone from month 3 and 
over tamsulosin alone from month 9. The percentage of men 
classified as IPSS responders at 24 month was significantly 
greater in the combination group for all three criteria (each 
comparison p  0.001). The increase in the peak urinary 
flow rate of the combination group was 2.4 mL/s (±0.12), 
significantly greater than 1.9 mL/s (±0.12) and 0.9 mL/s 
(±0.12) in the dutasteride group and the tamsulosin group, 
respectively (each p  0.003). The proportion of patients 
characterized as peak urinary flow rate responders was great-
est in the combination group. Mean decrease from baseline in 
total prostate volume was 26.9% (±0.62) in the combination 
therapy group, 28.0% (±0.61) in the dutasteride group, and 
0.0% (±0.84) in the tamsulosin group. Drug related adverse 
events were significantly greater in the combination therapy 
group compared to either monotherapy group, but 5% of 
men in each group withdrew from the study due to these 
events. Prostate cancer was reported in 58 men (21 in the 
combination group, 11 in the dutasteride group, and 26 in 
tamsulosin group). No cases of IFIS were reported.21
Conclusions
Dutasteride is the only dual inhibitor of 5α-reductase 
approved for use in the treatment of men with symptomatic 
BPH/BPE. Few drug interactions have been identified; how-
ever the use of this drug is contraindicated in men under age 
18 and in women owing to potential adverse effects on normal 
development of the male reproductive tract. Side effects 
occur in less than 5% and include impotence, loss of libido, 
ejaculatory dysfunction and gynecomastia. There is a poten-
tial risk of developing high-grade prostate cancer, although 
the overall risk of prostate cancer is reduced. Ongoing trials 
may support the use of dutasteride in the prevention of pros-
tate cancer (as with finasteride in the PCPT) and its effects 
on prostate cancer require further evaluation. Treatment in 
men with moderate to severe lower urinary tract symptoms 
results in improved symptoms, increased urinary flow rate, 
a reduced risk of urinary retention and need for surgical 
intervention, and an improvement in quality of life.
Tamsulosin is a competitive antagonist of α1A adrenore-
ceptors in the prostate and bladder neck. It has been shown 
in numerous studies to significantly improve symptom scores 
and peak urinary flow rates in men with symptomatic BPH/
BPE and long-term studies suggest these effects are durable. 
Drug interactions are rare and serious side effects occur in 
less than 2% of patients in any treatment group. Patients 
treated with tamsulosin who undergo cataract surgery should 
advise their ophthalmologist because of the risk of IFIS.
Two-year data from the multicenter CombAT study shows 
that combination therapy with dutasteride and tamsulosin 
results in significantly greater decreases in IPSS and signifi-
cant increases in peak urinary flow rates versus monotherapy 
with either dutasteride or tamsuolosin. Additionally, a signi-
ficantly greater reduction in total prostate and transition zone 
volume was achieved in the combination group as compared 
to monotherapy with tamsulosin. Adverse drug events are 
more common with combination therapy but study withdraw 
rates are similar among the treatment groups and are less 
than 5%.
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